Healthy Living: Acute Myeloid Leukemia

Most patients diagnosed with acute myeloid leukemia, or AML, face weeks of intense, brutal chemotherapy and maybe a stem cell transplant.

Even then, the American Cancer Society says only about 27 percent will live another five years.

In today’s Healthy Living, see how a Salt Lake City company is testing a targeted therapy that is showing promising early results.

The Alvocidib trial has enrolled 400 patients and is being run at nine sites in the U.S. and Canada.

It’s open only to people who have positive responses to the test.

Tolero expects to run a bigger randomized study soon and will have a better idea of how long Alvocidib can extend people’s lives.

 

Related Articles

Comments

comments